3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
6
Polycystic Ovary Syndrome
2
Obesity
2
Diabetes Mellitus
2
Stroke
1
Sedentary Behavior
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteoporosis
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myeloid, Acute
1
Kidney Diseases
1
Insulin Resistance
1
Hypertension
1
Heart Failure
1
Frailty
1
Endometrial Neoplasms
1
Diabetes Mellitus, Type 2
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Body Weight
1
Arthritis
1
Interventions
Ipilimumab
98
pembrolizumab
84
Nivolumab
82
aldesleukin
51
Cyclophosphamide
49
Interleukin-2
38
fludarabine phosphate
31
Vemurafenib
31
Dacarbazine
31
dabrafenib
29
trametinib
28
Temozolomide
26
fludarabine
25
CTLA-4 Antigen
18
Bevacizumab
18
Radiosurgery
15
Paclitaxel
15
Carboplatin
14
encorafenib
13
binimetinib
13
Introns
13
talimogene laherparepvec
12
Radiotherapy
12
Interferon alpha-2
12
spartalizumab
11
cobimetinib
10
atezolizumab
10
sargramostim
9
peginterferon alfa-2b
9
montanide ISA 51
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Melanoma
×
Resistance Training
×
Clear all
No trials found.